Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD2 | P25440 | 2/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958691 | 0.80 | BRD4 (0.36) | LMNAALDH1A1HTTATMBRD9 | |
| SCHEMBL27962400 | 0.80 | MEN1 (0.39) | LMNAALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL163968 | 0.78 | PDE10A (0.35) | LMNAALDH1A1HTTATMBRD9 | |
| SCHEMBL103897 | 0.78 | AURKA (0.36) | LMNAALDH1A1HTTATMBRD9 | |
| SCHEMBL612227 | 0.77 | LMNA (0.33) | LMNAALDH1A1HTTATMBRD9 | |
| SCHEMBL13729211 | 0.75 | ALDH1A1 (0.36) | LMNAALDH1A1HTTATMBRD9 | |
| SCHEMBL31612733 | 0.74 | THRA (0.34) | LMNAALDH1A1HTTATMKAT2B | |
| SCHEMBL31612726 | 0.74 | COMT (0.37) | LMNAALDH1A1HTTNOTUMKMT2A | |
| SCHEMBL31612727 | 0.74 | COMT (0.37) | LMNAALDH1A1HTTNOTUMKMT2A | |
| SCHEMBL13730108 | 0.70 | ALDH1A1 (0.35) | ALDH1A1HTTKMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-107074824-B | Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for the treatment of cancer | 基因泰克公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10155764-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-8618098-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-12-31 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097052-A1 | BROMODOMAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES (HK) | 2012-05-24 | — | — | US | disclosed |
| US-8124604-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | DEWDNEY NOLAN JAMES | 2011-05-05 | — | — | US | disclosed |
| EP-2297142-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105479-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | LMNA 3895/4885ALDH1A1 4560/4885HTT 4575/4885 |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | LMNA 1293/4885ALDH1A1 1794/4885HTT 2644/4885 |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | LMNA 4032/4885ALDH1A1 3880/4885HTT 4820/4885 |
| US-20120129845-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | LMNA 3895/4885ALDH1A1 4560/4885HTT 4575/4885 |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | LMNA 2339/4885ALDH1A1 2604/4885HTT 851/4885 |
| US-10155764-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC1 | LMNA 2339/4885ALDH1A1 2604/4885HTT 851/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | LMNA 1293/4885ALDH1A1 1794/4885HTT 2644/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | LMNA 1293/4885ALDH1A1 1794/4885HTT 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.